Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design
Dados Bibliográficos
BACKGROUND: The association between cost-sharing and receipt of medication for opioid use disorder (MOUD) is unknown. METHODS: We constructed a cohort of 10,513 commercially insured individuals with a new diagnosis of opioid use disorder and information on insurance cost-sharing in a large national deidentified claims database. We examined 4 cost-sharing measures: (1) pharmacy deductible; (2) medical service deductible; (3) pharmacy medication copay; and (4) medical office copay. We measured MOUD (naltrexone, buprenorphine, or methadone) initiation (within 14 d of diagnosis), engagement (second receipt within 34 d of first), and 6-month retention (continuous receipt without 14-d gap). We used multivariable logistic regression to assess the association between cost-sharing and MOUD initiation, engagement, and retention. We calculated total out-of-pocket costs in the 30 days following MOUD initiation for each type of MOUD. RESULTS: Of 10,513 individuals with incident opioid use disorder, 1202 (11%) initiated MOUD, 742 (7%) engaged, and 253 (2%) were retained in MOUD at 6 months. A high ($1000+) medical deductible was associated with a lower odds of initiation compared with no deductible (odds ratio: 0.85, 95% confidence interval: 0.74-0.98). We found no significant associations between other cost-sharing measures for initiation, engagement, or retention. Median initial 30-day out-of-pocket costs ranged from $100 for methadone to $710 for extended-release naltrexone. CONCLUSIONS: Among insurance plan cost-sharing measures, only medical services deductible showed an association with decreased MOUD initiation. Policy and benefit design should consider ways to reduce cost barriers to initiation and retention in MOUD
Deductible · Health insurance · Health plan · Medicare Part D · MEDLINE · Opioid use disorder · Plan (archaeology) · Variation (astronomy) · Medication Adherence and Compliance · Opioid Use Disorder Treatment · Pharmaceutical Economics and Policy
Insurance Instability for Patients With Opioid Use Disorder in the Year After Diagnosis
Expanding access to low‐barrier opioid use disorder treatment in non‐traditional settings
Real-world management of opioid use disorder in primary care 2015–2019
Medications for Opioid Use Disorder and Retention in Non-Intensive Outpatient Treatment
(RE-)AIMing for Rapid Uptake
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Barriers to Medications for Addiction Treatment
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality
Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019
A Caution Regarding Rules of Thumb for Variance Inflation Factors
Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue
Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder
| Obras citantes distintas | 5 |
|---|---|
| Citações por ano | 1,67 |
| Intervalo de citações | 2023 - 2026 (4) |
| Velocidade de citação | current |
| Altamente citado | Não |
| Tipos de citação | Neutras: 4 |